WELCOME TO GINWARD
Ginward Ltd. is a boutique corporate finance and consultancy company focused on connecting investors with opportunities in Europe and Asia. We also help companies expand their businesses into these regions through strategy advice and partnerships.
Building on the strong technical and financial expertise of its founders and venture partners, Ginward is a straightforward, pragmatic and professional partner for investment, expansion or fundraising in Europe and Asia.
Ginward is based in Singapore, Tokyo, London and the Netherlands, and is regulated by the Financial Conduct Authority of the United Kingdom.
SERVICES
CORPORATE FINANCE
AND INVESTMENTS
Ginward works closely with financial and industrial investors to diversify and strengthen their portfolio
business consultancy
and aGENCY
Ginward helps companies move into new markets in Europe or Asia
FUNDRAISING
Fundraising in all its forms is a key part of Ginward's services. We will work with you on the best way to present your business to the right investors
TEAM
Edward WILLEMS
Managing Director & Co-founder
Ginger HSIAO
Co-founder
Shang HSIAO
Co-founder and Venture Partner
Nettie BUITELAAR
Partner
Fumiaki YUMOTO, PhD
Country Head Japan, Managing Director
Jaap WIELING
Venture Partner and Scientific Advisor
William ONG, PhD
Technical Analyst
Ha Linh NGUYEN, PhD
Technical Analyst
Emilien DUGRAND, PhD
Scientific Analyst
Lyanne CHIN, PhD, RD
Technical Analyst
Shengyang JIN, PhD
Technical Analyst
Ali ASGAROV
Financial Analyst
Dr. Bert Tjeenk Willink
Advisor and Venture Partner
Nao YOSHIZAWA 吉澤尚
Advisor
Andrew LIN
Advisor
Clark SU
Advisor
Adam KIRBY
Advisor
Jerry HONG
Advisor
FOCUS
Ginward focuses, though not exclusively, on the following sectors identified as core areas of technological leadership in the target countries:
Our aim is to service the segment of the market that would benefit strongly from global access to investment or the broadening of international commercial reach. For this reason, we prefer to work with companies from the early growth to expansionary stages of their development or those with a strong IP content, in all cases with solid proof of concept or post-pre-clinical stage.